Get the Stockscreener App
26.29
2.18%
0.56
After Hours:
26.29
Pacira Biosciences Inc stock is traded at $26.29, with a volume of 932.83K.
It is up +2.18% in the last 24 hours and up +10.18% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$25.73
Open:
$25.74
24h Volume:
932.83K
Relative Volume:
1.44
Market Cap:
$1.13B
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
18.13
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
+9.59%
1M Performance:
+10.18%
6M Performance:
+7.53%
1Y Performance:
+32.78%
1-Day Range:
$25.16
$26.46
1-Week Range:
$23.63
$26.46
52-Week Range:
$18.17
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
26.29 | 1.11B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
118.66 | 51.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.33 | 45.46B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.79 | 34.62B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
493.99 | 21.03B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira Biosciences CFO cross sells $626k in shares - Investing.com
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - 富途牛牛
(PCRX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance - Sahm
Barclays Initiates Coverage of Pacira BioSciences (PCRX) with Equal-Weight Recommendation - Nasdaq
Pacira BioSciences (PCRX): Barclays Initiates Coverage with Equa - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Barclays - MarketBeat
102,668 Shares in Pacira BioSciences, Inc. $PCRX Bought by WINTON GROUP Ltd - MarketBeat
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
EV Market: Will Pacira BioSciences Inc. stock maintain momentum in 20252025 Earnings Surprises & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ
Will Pacira BioSciences Inc. (82P) stock rise with strong economyQuarterly Trade Report & Real-Time Volume Analysis Alerts - Newser
How Investors Are Reacting To Pacira BioSciences (PCRX) Spine Pain Trial Win And New FDA Clearance - Sahm
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out - ACCESS Newswire
Can Pacira BioSciences Inc. (82P) stock surprise with quarterly resultsJuly 2025 Reactions & Daily Profit Focused Stock Screening - Newser
Is Pacira BioSciences Inc. (82P) stock among top earnings plays2025 Fundamental Recap & Free Fast Entry Momentum Trade Alerts - Newser
Can Pacira BioSciences Inc. stock deliver surprise earnings beatWeekly Market Summary & Real-Time Price Movement Reports - Newser
Pacira Biosciences reports inducement grants under Nasdaq Listing Rule - marketscreener.com
Pacira BioSciences (PCRX) Awards Inducement Grants to New Employ - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences (Nasdaq: PCRX) issues 2,200 inducement RSUs to two new employees - Stock Titan
Why Pacira BioSciences Inc. (82P) stock attracts wealthy investorsJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Pacira’s iovera° shows better outcomes than RFA for chronic back pain By Investing.com - Investing.com South Africa
Does Pacira’s ioveradeg Pilot Data and Smart Tip Clearance Change The Bull Case For Pacira (PCRX)? - Yahoo Finance
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Pacira’s iovera° shows better outcomes than RFA for chronic back pain - Investing.com Nigeria
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain - Ortho Spine News
Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain - marketscreener.com
What macro factors could drive Pacira BioSciences Inc. (82P) stock higherWeekly Stock Recap & Weekly Setup with ROI Potential - Newser
American Century Companies Inc. Has $28.26 Million Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
How risky is Pacira BioSciences Inc. stock now2025 Price Action Summary & Weekly Sector Rotation Insights - BỘ NỘI VỤ
(PCRX) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Pacira BioSciences (PCRX): Valuation in Focus Following Moves to Defend EXPAREL Patents Against Generic Competition - Sahm
Pacira down after FDA filing for generic Exparel - MSN
Pacira BioSciences (PCRX): Assessing Valuation Following Legal Win That Delays EXPAREL Generic Approvals - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Connect - ACCESS Newswire
Is Pacira’s 30-Month Generic Delay for EXPAREL Shifting the Investment Outlook for PCRX? - Sahm
Pacira BioSciences Inc. Files Patent Infringement Lawsuit, Initiating 30-Month Stay of ANDA Approvals for EXPAREL® - Quiver Quantitative
Pacira BioSciences files Exparel patent infringement lawsuits against the WhiteOak Group and Qilu Pharmaceutical - marketscreener.com
Pacira BioSciences Files EXPAREL® Patent Infringement - GlobeNewswire
What analysts say about Pacira BioSciences Inc 82P stockRetail Trading Trends & Learn the Basics of Investing in 5 Days - earlytimes.in
Is Pacira BioSciences Inc a good long term investmentRSI Overbought/Oversold & Low Entry Investment Ideas - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Pacira BioSciences Inc. (82P) stock beat Nasdaq index returnsWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Pacira BioSciences, Inc. $PCRX Shares Sold by Bank of Montreal Can - MarketBeat
How to integrate Pacira BioSciences Inc. into portfolio analysis toolsSwing Trade & Reliable Volume Spike Trade Alerts - newser.com
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Is Pacira BioSciences Inc. (82P) stock attractive for dividend growth2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):